ASH 2021 | Preliminary results from NP40126: Glofitamab and R-CHOP in NHL
Martin Hutchings
• 12 Dec 2021
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the ongoing, Phase I NP40126 trial (NCT03467373) of glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, with R-CHOP in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) or treatment naïve diffuse large B-cell lymphoma (DLBCL). A promising safety profile was reported, with a toxicity similar to that of R-CHOP monotherapy, and a reduced rate of cytokine release syndrome (CRS) compared with glofitamab monotherapy. Treatment was additionally administered in a timely fashion, important in curing patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
